Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 22728514.
- Also identified by DOI 10.1053/j.gastro.2012.06.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alterations in intestinal microbiota are associated with obesity and insulin resistance. We studied the effects of infusing intestinal microbiota from lean donors to male recipients with metabolic syndrome on the recipients' microbiota composition and glucose metabolism. Subjects were assigned randomly to groups that were given small intestinal infusions of allogenic or autologous microbiota. Six weeks after infusion of microbiota from lean donors, insulin sensitivity of recipients increased (median rate of glucose disappearance changed from 26.2 to 45.3 μmol/kg/min; P < .05) along with levels of butyrate-producing intestinal microbiota. Intestinal microbiota might be developed as therapeutic agents to increase insulin sensitivity in humans; www.trialregister.nl; registered at the Dutch Trial Register (NTR1776).
Medical subject headings
- Blood Glucose
- Feces
- Insulin Resistance
- Intestine, Small
- Metabolic Syndrome
- Metagenome